MannKind Corporation - Jefferies Global Healthcare Conference in London - MANNKIND CORP
Explicit Guidance:
- Revenue Forecast: Q4 2026 revenue expected to be approximately $38 million (± variance noted).
- Long-term Revenue Run-rate: Anticipated $1 billion cumulative revenue from manufacturing and royalties between United Therapeutics (UT) and Mankind from 2026 through 2030.
- Profitability: Expectation to achieve profitability in Q4 2026.
- Milestone Income: Expectation of approximately $15 million in milestone payments from the UT collaboration related to Verlaine-Opeg (Opeg) and clinical supply revenue.
Business-Segment Outlook:
- Furosix (406):
- Growth Trajectory: Furosix ReadyFlow received approval in Q3; 75% of shipments converted immediately. 80% growth in new-to-brand prescriptions for Afreza Pediatrics (Fresa) with market share surpassing adult segments in early launch.
- Segment Penetration: Focus shifting to "hospital and IV diuretics" and "post-discharge readmission" segments. Hospital segment currently experiencing a temporary slowdown but expected to accelerate with full opening.
- Market Share: Transition from 0% OBI (all-body infuser) share 4 weeks pre-launch to 56% share 4 weeks post-launch, rising to 73% in the subsequent 4-week period; 90% of community prescriptions now for ReadyFlow.
- Future Formulations: Filing for a 40-mg Furosix formulation planned for next year; launching a high-concentration Afreza formulation for Type 2 diabetes (targeting 16–20 units per meal in one inhalation) in 2026 and beyond.
- Afreza (Fresa):
- Pediatric Focus: Doubling down on adult segment focus in 2027; pediatric adoption is 2x adult adoption in first 90 days with strong refill rates.
- New Products: Launching a 2-unit low-dose cartridge next year to support newly diagnosed children in the "honeymoon period."
- Commercial Strategy: Reallocating sales force to nephrology and cardiology to reverse prior share-of-voice decline in adult segments.
- United Therapeutics (UT) Collaboration:
- Tybeso DPI: Returning to growth in Q3 2026; expected to continue success in Q4 and beyond with expansion into IPF and PPF. Mankind to be the sole source manufacturer for Tybeso.
- Verlaine-Opeg: Once-a-day prostacyclin expected to receive approval in 2027 for multiple indications (pH, pH-ILD, IPF, PPF). Mankind to manufacture this product exclusively.
- Capacity: Manufacturing capacity expansion supports up to 250,000 patients; second plant in North Carolina built for Verlaine-Opeg.
- Furosix (406):
Market and Competitive Outlook:
- IPF Therapeutics: Management anticipates three "shots on goal" in the IPF space: Relenopeg (UTI), Tybeso DPI, and Natentanib (Mankind's own). The market is characterized by high unmet need and historical failure rates for new treatments.
- Inhaled Insulin Market: Strategy to break the "pump mindset" via the "Afreza Inhale First" program (initial dose in hospital within 10 days of diagnosis). Goal to reach 100 patients in this trial by mid-2027.
- Competitive Positioning: Furosix ReadyFlow is positioned as the "first and only IV equivalent diuretic" with a three-to-four-quarter conversion timeline previously expected, but observed to be completed within the first 30 days.
Macro / Industry Outlook:
- Economic Impact: Management views the UT collaboration revenue stream as "durable" and "economic background" for the company, countering earlier market noise regarding its longevity.
- Regulatory Environment: Positive feedback received from FDA regarding Natentanib Phase 2 (INFLOW2) trial design and IPF trial tolerability; no major safety signals observed in Phase 1B (60% of patients reported no cough increase, 30% mild cough).
- Manufacturing Shift: Shift of Tybeso manufacturing to Mankind (sole source) represents a significant structural change, previously anticipated to be North Carolina-based by UT.
Strategic Initiatives:
- Natentanib Clinical Progress:
- Timeline: Moving into Phase 2 (INFLOW2) in the U.S. and globally very shortly (early 2026); target enrollment of 153 patients across ~100 sites (added 15 sites).
- Dosing: Resized from QID (Quadruple Daily) to BID (Twice Daily) regimen to reduce complexity; aiming for data readout in the first half of 2028, potentially pulled forward to early 2028.
- Goal: Establish efficacy at 4mg BID (target dose) vs. 2mg BID vs. placebo.
- Digital Integration: Launching "Inhale IQ," a hardware adapter connecting the inhaler to CGM, expected to launch next year to enable dose tracking for parents and clinicians.
- "Inhale First" Pilot: Expanding to 10 top U.S. centers with a goal of 100 patients by mid-2027 to demonstrate the efficacy of inhaled insulin as an initial therapy for new pediatric diagnoses.
- Natentanib Clinical Progress:
Risks and Headwinds to Outlook:
- Clinical Execution: Natentanib Phase 2 enrollment was slowed this year due to protocol resizing (QID to BID) and FDA approval cycles for new protocols.
- Market Complexity: Penetration of the "emergency department" segment for Furosix is described as the "hardest segment" due to system complexities.
- Competitive Landscape: The inhaled insulin market faces safety overhangs and "pump mindset" barriers; success depends on changing prescriber behavior.
- Macroeconomic/Logistical: Recent co-pilot outbreaks and airline shutdowns are noted as external variables that could impact logistics, though Mankind reported record referrals despite these headwinds.
Management Tone on the Future:
- Confidence Level: High confidence in the durability of the UT revenue stream and the commercial success of Furosix ReadyFlow and Afreza Pediatrics.
- Strategic Pivot: Acknowledgment of a past "eye on the ball" lapse in the adult Afreza segment, now corrected by a specific "double down" strategy on adult sales force focus.
- Optimism: Describes the future as "very bright," citing strong momentum across all three growth engines (Commercial revenue, UT collaboration, and long-term pipeline).
Miscellaneous:
- Trial Details: Natentanib Phase 1B (July 2026) included 27 IPF patients with zero discontinuations due to cough. Phase 2 INFLOW2 design tests 4mg BID vs. placebo and 2mg BID vs. placebo.
- Manufacturing Economics: The dual plant strategy (Mankind and UT's North Carolina facility) is expected to provide "adorable economic background" (likely a transcription error for "robust" or "favorable") for years to come.
- Pricing/Access: New 2-unit cartridge and high-concentration formulations are designed to improve patient adherence and reduce the volume of powder inhaled.
- Company
- MANNKIND CORP
- Keywords
- MANNKIND CORP